Xavier Charmetant
Overview
Explore the profile of Xavier Charmetant including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
226
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Charmetant X, Rigault G, Chen C, Kaminski H, Visentin J, Taton B, et al.
Transpl Int
. 2025 Feb;
38:12859.
PMID: 39944220
The generation of donor-specific antibodies (DSA) requires that alloreactive B cells receive help from follicular helper T (T) cells. Recent works have suggested that γδ T cells could contribute to...
2.
Charmetant X, Pettigrew G, Thaunat O
Transpl Int
. 2024 Nov;
37:13523.
PMID: 39588197
In transplantation, genetic differences between donor and recipient trigger immune responses that cause graft rejection. Allorecognition, the process by which the immune system discriminates allogeneic grafts, targets major histocompatibility complex...
3.
Espi M, Charmetant X, Benotmane I, Lefsihane K, Barateau V, Gallais F, et al.
J Med Virol
. 2024 Nov;
96(11):e70037.
PMID: 39530340
Kidney transplant recipients (KTRs) are highly vulnerable to COVID-19. An intensified scheme of vaccination offers short-term protection to the 50%-75% of KTRs able to develop a germinal center reaction, required...
4.
Espi M, Charmetant X, Mathieu C, Lalande A, Decimo D, Koppe L, et al.
Kidney Int Rep
. 2023 Jan;
8(4):907-911.
PMID: 36644712
No abstract available.
5.
Charmetant X, Chen C, Hamada S, Goncalves D, Saison C, Rabeyrin M, et al.
Sci Transl Med
. 2022 Sep;
14(663):eabg1046.
PMID: 36130013
The generation of antibodies against donor-specific major histocompatibility complex (MHC) antigens, a type of donor-specific antibodies (DSAs), after transplantation requires that recipient's allospecific B cells receive help from T cells....
6.
Shyfrin S, Ferren M, Perrin-Cocon L, Espi M, Charmetant X, Brailly M, et al.
J Tissue Eng
. 2022 Sep;
13:20417314221122130.
PMID: 36093433
Kidney pathology is frequently reported in patients hospitalized with COVID-19, the pandemic disease caused by the Severe acute respiratory coronavirus 2 (SARS-CoV-2). However, due to a lack of suitable study...
7.
Charmetant X, Espi M, Barba T, Ovize A, Morelon E, Mathieu C, et al.
Am J Transplant
. 2022 Feb;
22(5):1442-1450.
PMID: 35114060
Kidney transplant recipients (KTRs) have reduced ability to mount adequate antibody response after two doses of the COVID-19 mRNA vaccine. French health authorities have allowed a third booster dose (D3)...
8.
Charmetant X, Espi M, Benotmane I, Barateau V, Heibel F, Buron F, et al.
Sci Transl Med
. 2022 Feb;
14(636):eabl6141.
PMID: 35103481
Transplant recipients, who receive therapeutic immunosuppression to prevent graft rejection, are characterized by high coronavirus disease 2019 (COVID-19)-related mortality and defective response to vaccines. We observed that previous infection with...
9.
Espi M, Charmetant X, Barba T, Mathieu C, Pelletier C, Koppe L, et al.
Kidney Int
. 2021 Dec;
101(2):390-402.
PMID: 34856313
The level of protection achieved by the standard two doses of COVID-19 mRNA vaccines in patients receiving maintenance hemodialysis (MHD) remains unclear. To study this we used the French Renal...
10.
Espi M, Charmetant X, Barba T, Koppe L, Pelletier C, Kalbacher E, et al.
Kidney Int
. 2021 Jul;
100(4):928-936.
PMID: 34284044
Patients on maintenance hemodialysis (MHD), which are at high risk of infection by SARS-CoV-2 virus and death due to COVID-19, have been prioritized for vaccination. However, because they were excluded...